Request for Covid-19 Impact Assessment of this Report

Healthcare

COVID-19 Impact on Global Immune Check Point Inhibitor, Market Insights and Forecast to 2026

  • BMR3903673
  • 149 Pages
  • June 2020
  • Healthcare
Download Sample    Get Discount   
 
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Immune Check Point Inhibitor market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyses the impact of Coronavirus COVID-19 on the Immune Check Point Inhibitor industry.

Based on our recent survey, we have several different scenarios about the Immune Check Point Inhibitor YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Immune Check Point Inhibitor will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Immune Check Point Inhibitor market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Immune Check Point Inhibitor market in terms of both revenue and volume.

Players, stakeholders, and other participants in the global Immune Check Point Inhibitor market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on sales (volume), revenue and forecast by each application segment in terms of sales and revenue and forecast by each type segment in terms of revenue for the period 2015-2026.

Sales and Pricing Analyses

Readers are provided with deeper sales analysis and pricing analysis for the global Immune Check Point Inhibitor market. As part of sales analysis, the report offers accurate statistics and figures for sales and revenue by region, by each type segment for the period 2015-2026.

In the pricing analysis section of the report, readers are provided with validated statistics and figures for the price by players and price by region for the period 2015-2020 and price by each type segment for the period 2015-2020.

Regional and Country-level Analysis

The report offers an exhaustive geographical analysis of the global Immune Check Point Inhibitor market, covering important regions, viz, North America, Europe, China and Japan. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of sales for the period 2015-2026.

Competition Analysis

In the competitive analysis section of the report, leading as well as prominent players of the global Immune Check Point Inhibitor market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on sales by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Immune Check Point Inhibitor market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Immune Check Point Inhibitor market.

The following manufacturers are covered in this report:

Advaxis

Agenus

Amgen

Bristol Myers Squibb

Faron Pharmaceuticals

Genentech

Genocea

Incyte Corporation

Innate Pharma

Kite Pharma

MacroGenics

Merck

NewLink Genetics Corp

Sorrento Therapeutics

TG Therapeutics

Immune Check Point Inhibitor Breakdown Data by Type

CTLA 4

PD 1

Others

Immune Check Point Inhibitor Breakdown Data by Application

Medical Care

Experiment

Others

1 Study Coverage

1.1 Immune Check Point Inhibitor Product Introduction

1.2 Market Segments

1.3 Key Immune Check Point Inhibitor Manufacturers Covered: Ranking by Revenue

1.4 Market by Type

1.4.1 Global Immune Check Point Inhibitor Market Size Growth Rate by Type

1.4.2 CTLA 4

1.4.3 PD 1

1.4.4 Others

1.5 Market by Application

1.5.1 Global Immune Check Point Inhibitor Market Size Growth Rate by Application

1.5.2 Medical Care

1.5.3 Experiment

1.5.4 Others

1.6 Coronavirus Disease 2019 (Covid-19): Immune Check Point Inhibitor Industry Impact

1.6.1 How the Covid-19 is Affecting the Immune Check Point Inhibitor Industry

1.6.1.1 Immune Check Point Inhibitor Business Impact Assessment - Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Immune Check Point Inhibitor Potential Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Immune Check Point Inhibitor Players to Combat Covid-19 Impact

1.7 Study Objectives

1.8 Years Considered

2 Executive Summary

2.1 Global Immune Check Point Inhibitor Market Size Estimates and Forecasts

2.1.1 Global Immune Check Point Inhibitor Revenue 2015-2026

2.1.2 Global Immune Check Point Inhibitor Sales 2015-2026

2.2 Immune Check Point Inhibitor Market Size by Region: 2020 Versus 2026

2.2.1 Global Immune Check Point Inhibitor Retrospective Market Scenario in Sales by Region: 2015-2020

2.2.2 Global Immune Check Point Inhibitor Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Immune Check Point Inhibitor Competitor Landscape by Players

3.1 Immune Check Point Inhibitor Sales by Manufacturers

3.1.1 Immune Check Point Inhibitor Sales by Manufacturers (2015-2020)

3.1.2 Immune Check Point Inhibitor Sales Market Share by Manufacturers (2015-2020)

3.2 Immune Check Point Inhibitor Revenue by Manufacturers

3.2.1 Immune Check Point Inhibitor Revenue by Manufacturers (2015-2020)

3.2.2 Immune Check Point Inhibitor Revenue Share by Manufacturers (2015-2020)

3.2.3 Global Immune Check Point Inhibitor Market Concentration Ratio (CR5 and HHI) (2015-2020)

3.2.4 Global Top 10 and Top 5 Companies by Immune Check Point Inhibitor Revenue in 2019

3.2.5 Global Immune Check Point Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.3 Immune Check Point Inhibitor Price by Manufacturers

3.4 Immune Check Point Inhibitor Manufacturing Base Distribution, Product Types

3.4.1 Immune Check Point Inhibitor Manufacturers Manufacturing Base Distribution, Headquarters

3.4.2 Manufacturers Immune Check Point Inhibitor Product Type

3.4.3 Date of International Manufacturers Enter into Immune Check Point Inhibitor Market

3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

4.1 Global Immune Check Point Inhibitor Market Size by Type (2015-2020)

4.1.1 Global Immune Check Point Inhibitor Sales by Type (2015-2020)

4.1.2 Global Immune Check Point Inhibitor Revenue by Type (2015-2020)

4.1.3 Immune Check Point Inhibitor Average Selling Price (ASP) by Type (2015-2026)

4.2 Global Immune Check Point Inhibitor Market Size Forecast by Type (2021-2026)

4.2.1 Global Immune Check Point Inhibitor Sales Forecast by Type (2021-2026)

4.2.2 Global Immune Check Point Inhibitor Revenue Forecast by Type (2021-2026)

4.2.3 Immune Check Point Inhibitor Average Selling Price (ASP) Forecast by Type (2021-2026)

4.3 Global Immune Check Point Inhibitor Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Breakdown Data by Application (2015-2026)

5.1 Global Immune Check Point Inhibitor Market Size by Application (2015-2020)

5.1.1 Global Immune Check Point Inhibitor Sales by Application (2015-2020)

5.1.2 Global Immune Check Point Inhibitor Revenue by Application (2015-2020)

5.1.3 Immune Check Point Inhibitor Price by Application (2015-2020)

5.2 Immune Check Point Inhibitor Market Size Forecast by Application (2021-2026)

5.2.1 Global Immune Check Point Inhibitor Sales Forecast by Application (2021-2026)

5.2.2 Global Immune Check Point Inhibitor Revenue Forecast by Application (2021-2026)

5.2.3 Global Immune Check Point Inhibitor Price Forecast by Application (2021-2026)

6 North America

6.1 North America Immune Check Point Inhibitor by Country

6.1.1 North America Immune Check Point Inhibitor Sales by Country

6.1.2 North America Immune Check Point Inhibitor Revenue by Country

6.1.3 U.S.

6.1.4 Canada

6.2 North America Immune Check Point Inhibitor Market Facts & Figures by Type

6.3 North America Immune Check Point Inhibitor Market Facts & Figures by Application

7 Europe

7.1 Europe Immune Check Point Inhibitor by Country

7.1.1 Europe Immune Check Point Inhibitor Sales by Country

7.1.2 Europe Immune Check Point Inhibitor Revenue by Country

7.1.3 Germany

7.1.4 France

7.1.5 U.K.

7.1.6 Italy

7.1.7 Russia

7.2 Europe Immune Check Point Inhibitor Market Facts & Figures by Type

7.3 Europe Immune Check Point Inhibitor Market Facts & Figures by Application

8 Asia Pacific

8.1 Asia Pacific Immune Check Point Inhibitor by Region

8.1.1 Asia Pacific Immune Check Point Inhibitor Sales by Region

8.1.2 Asia Pacific Immune Check Point Inhibitor Revenue by Region

8.1.3 China

8.1.4 Japan

8.1.5 South Korea

8.1.6 India

8.1.7 Australia

8.1.8 Taiwan

8.1.9 Indonesia

8.1.10 Thailand

8.1.11 Malaysia

8.1.12 Philippines

8.1.13 Vietnam

8.2 Asia Pacific Immune Check Point Inhibitor Market Facts & Figures by Type

8.3 Asia Pacific Immune Check Point Inhibitor Market Facts & Figures by Application

9 Latin America

9.1 Latin America Immune Check Point Inhibitor by Country

9.1.1 Latin America Immune Check Point Inhibitor Sales by Country

9.1.2 Latin America Immune Check Point Inhibitor Revenue by Country

9.1.3 Mexico

9.1.4 Brazil

9.1.5 Argentina

9.2 Central & South America Immune Check Point Inhibitor Market Facts & Figures by Type

9.3 Central & South America Immune Check Point Inhibitor Market Facts & Figures by Application

10 Middle East and Africa

10.1 Middle East and Africa Immune Check Point Inhibitor by Country

10.1.1 Middle East and Africa Immune Check Point Inhibitor Sales by Country

10.1.2 Middle East and Africa Immune Check Point Inhibitor Revenue by Country

10.1.3 Turkey

10.1.4 Saudi Arabia

10.1.5 U.A.E

10.2 Middle East and Africa Immune Check Point Inhibitor Market Facts & Figures by Type

10.3 Middle East and Africa Immune Check Point Inhibitor Market Facts & Figures by Application

11 Company Profiles

11.1 Advaxis

11.1.1 Advaxis Corporation Information

11.1.2 Advaxis Description, Business Overview and Total Revenue

11.1.3 Advaxis Sales, Revenue and Gross Margin (2015-2020)

11.1.4 Advaxis Immune Check Point Inhibitor Products Offered

11.1.5 Advaxis Recent Development

11.2 Agenus

11.2.1 Agenus Corporation Information

11.2.2 Agenus Description, Business Overview and Total Revenue

11.2.3 Agenus Sales, Revenue and Gross Margin (2015-2020)

11.2.4 Agenus Immune Check Point Inhibitor Products Offered

11.2.5 Agenus Recent Development

11.3 Amgen

11.3.1 Amgen Corporation Information

11.3.2 Amgen Description, Business Overview and Total Revenue

11.3.3 Amgen Sales, Revenue and Gross Margin (2015-2020)

11.3.4 Amgen Immune Check Point Inhibitor Products Offered

11.3.5 Amgen Recent Development

11.4 Bristol Myers Squibb

11.4.1 Bristol Myers Squibb Corporation Information

11.4.2 Bristol Myers Squibb Description, Business Overview and Total Revenue

11.4.3 Bristol Myers Squibb Sales, Revenue and Gross Margin (2015-2020)

11.4.4 Bristol Myers Squibb Immune Check Point Inhibitor Products Offered

11.4.5 Bristol Myers Squibb Recent Development

11.5 Faron Pharmaceuticals

11.5.1 Faron Pharmaceuticals Corporation Information

11.5.2 Faron Pharmaceuticals Description, Business Overview and Total Revenue

11.5.3 Faron Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)

11.5.4 Faron Pharmaceuticals Immune Check Point Inhibitor Products Offered

11.5.5 Faron Pharmaceuticals Recent Development

11.6 Genentech

11.6.1 Genentech Corporation Information

11.6.2 Genentech Description, Business Overview and Total Revenue

11.6.3 Genentech Sales, Revenue and Gross Margin (2015-2020)

11.6.4 Genentech Immune Check Point Inhibitor Products Offered

11.6.5 Genentech Recent Development

11.7 Genocea

11.7.1 Genocea Corporation Information

11.7.2 Genocea Description, Business Overview and Total Revenue

11.7.3 Genocea Sales, Revenue and Gross Margin (2015-2020)

11.7.4 Genocea Immune Check Point Inhibitor Products Offered

11.7.5 Genocea Recent Development

11.8 Incyte Corporation

11.8.1 Incyte Corporation Corporation Information

11.8.2 Incyte Corporation Description, Business Overview and Total Revenue

11.8.3 Incyte Corporation Sales, Revenue and Gross Margin (2015-2020)

11.8.4 Incyte Corporation Immune Check Point Inhibitor Products Offered

11.8.5 Incyte Corporation Recent Development

11.9 Innate Pharma

11.9.1 Innate Pharma Corporation Information

11.9.2 Innate Pharma Description, Business Overview and Total Revenue

11.9.3 Innate Pharma Sales, Revenue and Gross Margin (2015-2020)

11.9.4 Innate Pharma Immune Check Point Inhibitor Products Offered

11.9.5 Innate Pharma Recent Development

11.10 Kite Pharma

11.10.1 Kite Pharma Corporation Information

11.10.2 Kite Pharma Description, Business Overview and Total Revenue

11.10.3 Kite Pharma Sales, Revenue and Gross Margin (2015-2020)

11.10.4 Kite Pharma Immune Check Point Inhibitor Products Offered

11.10.5 Kite Pharma Recent Development

11.1 Advaxis

11.1.1 Advaxis Corporation Information

11.1.2 Advaxis Description, Business Overview and Total Revenue

11.1.3 Advaxis Sales, Revenue and Gross Margin (2015-2020)

11.1.4 Advaxis Immune Check Point Inhibitor Products Offered

11.1.5 Advaxis Recent Development

11.12 Merck

11.12.1 Merck Corporation Information

11.12.2 Merck Description, Business Overview and Total Revenue

11.12.3 Merck Sales, Revenue and Gross Margin (2015-2020)

11.12.4 Merck Products Offered

11.12.5 Merck Recent Development

11.13 NewLink Genetics Corp

11.13.1 NewLink Genetics Corp Corporation Information

11.13.2 NewLink Genetics Corp Description, Business Overview and Total Revenue

11.13.3 NewLink Genetics Corp Sales, Revenue and Gross Margin (2015-2020)

11.13.4 NewLink Genetics Corp Products Offered

11.13.5 NewLink Genetics Corp Recent Development

11.14 Sorrento Therapeutics

11.14.1 Sorrento Therapeutics Corporation Information

11.14.2 Sorrento Therapeutics Description, Business Overview and Total Revenue

11.14.3 Sorrento Therapeutics Sales, Revenue and Gross Margin (2015-2020)

11.14.4 Sorrento Therapeutics Products Offered

11.14.5 Sorrento Therapeutics Recent Development

11.15 TG Therapeutics

11.15.1 TG Therapeutics Corporation Information

11.15.2 TG Therapeutics Description, Business Overview and Total Revenue

11.15.3 TG Therapeutics Sales, Revenue and Gross Margin (2015-2020)

11.15.4 TG Therapeutics Products Offered

11.15.5 TG Therapeutics Recent Development

12 Future Forecast by Regions (Countries) (2021-2026)

12.1 Immune Check Point Inhibitor Market Estimates and Projections by Region

12.1.1 Global Immune Check Point Inhibitor Sales Forecast by Regions 2021-2026

12.1.2 Global Immune Check Point Inhibitor Revenue Forecast by Regions 2021-2026

12.2 North America Immune Check Point Inhibitor Market Size Forecast (2021-2026)

12.2.1 North America: Immune Check Point Inhibitor Sales Forecast (2021-2026)

12.2.2 North America: Immune Check Point Inhibitor Revenue Forecast (2021-2026)

12.2.3 North America: Immune Check Point Inhibitor Market Size Forecast by Country (2021-2026)

12.3 Europe Immune Check Point Inhibitor Market Size Forecast (2021-2026)

12.3.1 Europe: Immune Check Point Inhibitor Sales Forecast (2021-2026)

12.3.2 Europe: Immune Check Point Inhibitor Revenue Forecast (2021-2026)

12.3.3 Europe: Immune Check Point Inhibitor Market Size Forecast by Country (2021-2026)

12.4 Asia Pacific Immune Check Point Inhibitor Market Size Forecast (2021-2026)

12.4.1 Asia Pacific: Immune Check Point Inhibitor Sales Forecast (2021-2026)

12.4.2 Asia Pacific: Immune Check Point Inhibitor Revenue Forecast (2021-2026)

12.4.3 Asia Pacific: Immune Check Point Inhibitor Market Size Forecast by Region (2021-2026)

12.5 Latin America Immune Check Point Inhibitor Market Size Forecast (2021-2026)

12.5.1 Latin America: Immune Check Point Inhibitor Sales Forecast (2021-2026)

12.5.2 Latin America: Immune Check Point Inhibitor Revenue Forecast (2021-2026)

12.5.3 Latin America: Immune Check Point Inhibitor Market Size Forecast by Country (2021-2026)

12.6 Middle East and Africa Immune Check Point Inhibitor Market Size Forecast (2021-2026)

12.6.1 Middle East and Africa: Immune Check Point Inhibitor Sales Forecast (2021-2026)

12.6.2 Middle East and Africa: Immune Check Point Inhibitor Revenue Forecast (2021-2026)

12.6.3 Middle East and Africa: Immune Check Point Inhibitor Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

13.1 Market Opportunities and Drivers

13.2 Market Challenges

13.3 Market Risks/Restraints

13.4 Porter’s Five Forces Analysis

13.5 Primary Interviews with Key Immune Check Point Inhibitor Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

14.1 Value Chain Analysis

14.2 Immune Check Point Inhibitor Customers

14.3 Sales Channels Analysis

14.3.1 Sales Channels

14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

16.1 Research Methodology

16.1.1 Methodology/Research Approach

16.1.2 Data Source

16.2 Author Details

List of Tables

Table 1. Immune Check Point Inhibitor Market Segments

Table 2. Ranking of Global Top Immune Check Point Inhibitor Manufacturers by Revenue (US$ Million) in 2019

Table 3. Global Immune Check Point Inhibitor Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)

Table 4. Major Manufacturers of CTLA 4

Table 5. Major Manufacturers of PD 1

Table 6. Major Manufacturers of Others

Table 7. COVID-19 Impact Global Market: (Four Immune Check Point Inhibitor Market Size Forecast Scenarios)

Table 8. Opportunities and Trends for Immune Check Point Inhibitor Players in the COVID-19 Landscape

Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 10. Key Regions/Countries Measures against Covid-19 Impact

Table 11. Proposal for Immune Check Point Inhibitor Players to Combat Covid-19 Impact

Table 12. Global Immune Check Point Inhibitor Market Size Growth Rate by Application 2020-2026 (K Pcs)

Table 13. Global Immune Check Point Inhibitor Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026

Table 14. Global Immune Check Point Inhibitor Sales by Regions 2015-2020 (K Pcs)

Table 15. Global Immune Check Point Inhibitor Sales Market Share by Regions (2015-2020)

Table 16. Global Immune Check Point Inhibitor Revenue by Regions 2015-2020 (US$ Million)

Table 17. Global Immune Check Point Inhibitor Sales by Manufacturers (2015-2020) (K Pcs)

Table 18. Global Immune Check Point Inhibitor Sales Share by Manufacturers (2015-2020)

Table 19. Global Immune Check Point Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)

Table 20. Global Immune Check Point Inhibitor by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immune Check Point Inhibitor as of 2019)

Table 21. Immune Check Point Inhibitor Revenue by Manufacturers (2015-2020) (US$ Million)

Table 22. Immune Check Point Inhibitor Revenue Share by Manufacturers (2015-2020)

Table 23. Key Manufacturers Immune Check Point Inhibitor Price (2015-2020) (USD/Pcs)

Table 24. Immune Check Point Inhibitor Manufacturers Manufacturing Base Distribution and Headquarters

Table 25. Manufacturers Immune Check Point Inhibitor Product Type

Table 26. Date of International Manufacturers Enter into Immune Check Point Inhibitor Market

Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 28. Global Immune Check Point Inhibitor Sales by Type (2015-2020) (K Pcs)

Table 29. Global Immune Check Point Inhibitor Sales Share by Type (2015-2020)

Table 30. Global Immune Check Point Inhibitor Revenue by Type (2015-2020) (US$ Million)

Table 31. Global Immune Check Point Inhibitor Revenue Share by Type (2015-2020)

Table 32. Immune Check Point Inhibitor Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)

Table 33. Global Immune Check Point Inhibitor Sales by Application (2015-2020) (K Pcs)

Table 34. Global Immune Check Point Inhibitor Sales Share by Application (2015-2020)

Table 35. North America Immune Check Point Inhibitor Sales by Country (2015-2020) (K Pcs)

Table 36. North America Immune Check Point Inhibitor Sales Market Share by Country (2015-2020)

Table 37. North America Immune Check Point Inhibitor Revenue by Country (2015-2020) (US$ Million)

Table 38. North America Immune Check Point Inhibitor Revenue Market Share by Country (2015-2020)

Table 39. North America Immune Check Point Inhibitor Sales by Type (2015-2020) (K Pcs)

Table 40. North America Immune Check Point Inhibitor Sales Market Share by Type (2015-2020)

Table 41. North America Immune Check Point Inhibitor Sales by Application (2015-2020) (K Pcs)

Table 42. North America Immune Check Point Inhibitor Sales Market Share by Application (2015-2020)

Table 43. Europe Immune Check Point Inhibitor Sales by Country (2015-2020) (K Pcs)

Table 44. Europe Immune Check Point Inhibitor Sales Market Share by Country (2015-2020)

Table 45. Europe Immune Check Point Inhibitor Revenue by Country (2015-2020) (US$ Million)

Table 46. Europe Immune Check Point Inhibitor Revenue Market Share by Country (2015-2020)

Table 47. Europe Immune Check Point Inhibitor Sales by Type (2015-2020) (K Pcs)

Table 48. Europe Immune Check Point Inhibitor Sales Market Share by Type (2015-2020)

Table 49. Europe Immune Check Point Inhibitor Sales by Application (2015-2020) (K Pcs)

Table 50. Europe Immune Check Point Inhibitor Sales Market Share by Application (2015-2020)

Table 51. Asia Pacific Immune Check Point Inhibitor Sales by Region (2015-2020) (K Pcs)

Table 52. Asia Pacific Immune Check Point Inhibitor Sales Market Share by Region (2015-2020)

Table 53. Asia Pacific Immune Check Point Inhibitor Revenue by Region (2015-2020) (US$ Million)

Table 54. Asia Pacific Immune Check Point Inhibitor Revenue Market Share by Region (2015-2020)

Table 55. Asia Pacific Immune Check Point Inhibitor Sales by Type (2015-2020) (K Pcs)

Table 56. Asia Pacific Immune Check Point Inhibitor Sales Market Share by Type (2015-2020)

Table 57. Asia Pacific Immune Check Point Inhibitor Sales by Application (2015-2020) (K Pcs)

Table 58. Asia Pacific Immune Check Point Inhibitor Sales Market Share by Application (2015-2020)

Table 59. Latin America Immune Check Point Inhibitor Sales by Country (2015-2020) (K Pcs)

Table 60. Latin America Immune Check Point Inhibitor Sales Market Share by Country (2015-2020)

Table 61. Latin Americaa Immune Check Point Inhibitor Revenue by Country (2015-2020) (US$ Million)

Table 62. Latin America Immune Check Point Inhibitor Revenue Market Share by Country (2015-2020)

Table 63. Latin America Immune Check Point Inhibitor Sales by Type (2015-2020) (K Pcs)

Table 64. Latin America Immune Check Point Inhibitor Sales Market Share by Type (2015-2020)

Table 65. Latin America Immune Check Point Inhibitor Sales by Application (2015-2020) (K Pcs)

Table 66. Latin America Immune Check Point Inhibitor Sales Market Share by Application (2015-2020)

Table 67. Middle East and Africa Immune Check Point Inhibitor Sales by Country (2015-2020) (K Pcs)

Table 68. Middle East and Africa Immune Check Point Inhibitor Sales Market Share by Country (2015-2020)

Table 69. Middle East and Africa Immune Check Point Inhibitor Revenue by Country (2015-2020) (US$ Million)

Table 70. Middle East and Africa Immune Check Point Inhibitor Revenue Market Share by Country (2015-2020)

Table 71. Middle East and Africa Immune Check Point Inhibitor Sales by Type (2015-2020) (K Pcs)

Table 72. Middle East and Africa Immune Check Point Inhibitor Sales Market Share by Type (2015-2020)

Table 73. Middle East and Africa Immune Check Point Inhibitor Sales by Application (2015-2020) (K Pcs)

Table 74. Middle East and Africa Immune Check Point Inhibitor Sales Market Share by Application (2015-2020)

Table 75. Advaxis Corporation Information

Table 76. Advaxis Description and Major Businesses

Table 77. Advaxis Immune Check Point Inhibitor Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 78. Advaxis Product

Table 79. Advaxis Recent Development

Table 80. Agenus Corporation Information

Table 81. Agenus Description and Major Businesses

Table 82. Agenus Immune Check Point Inhibitor Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 83. Agenus Product

Table 84. Agenus Recent Development

Table 85. Amgen Corporation Information

Table 86. Amgen Description and Major Businesses

Table 87. Amgen Immune Check Point Inhibitor Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 88. Amgen Product

Table 89. Amgen Recent Development

Table 90. Bristol Myers Squibb Corporation Information

Table 91. Bristol Myers Squibb Description and Major Businesses

Table 92. Bristol Myers Squibb Immune Check Point Inhibitor Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 93. Bristol Myers Squibb Product

Table 94. Bristol Myers Squibb Recent Development

Table 95. Faron Pharmaceuticals Corporation Information

Table 96. Faron Pharmaceuticals Description and Major Businesses

Table 97. Faron Pharmaceuticals Immune Check Point Inhibitor Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 98. Faron Pharmaceuticals Product

Table 99. Faron Pharmaceuticals Recent Development

Table 100. Genentech Corporation Information

Table 101. Genentech Description and Major Businesses

Table 102. Genentech Immune Check Point Inhibitor Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 103. Genentech Product

Table 104. Genentech Recent Development

Table 105. Genocea Corporation Information

Table 106. Genocea Description and Major Businesses

Table 107. Genocea Immune Check Point Inhibitor Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 108. Genocea Product

Table 109. Genocea Recent Development

Table 110. Incyte Corporation Corporation Information

Table 111. Incyte Corporation Description and Major Businesses

Table 112. Incyte Corporation Immune Check Point Inhibitor Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 113. Incyte Corporation Product

Table 114. Incyte Corporation Recent Development

Table 115. Innate Pharma Corporation Information

Table 116. Innate Pharma Description and Major Businesses

Table 117. Innate Pharma Immune Check Point Inhibitor Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 118. Innate Pharma Product

Table 119. Innate Pharma Recent Development

Table 120. Kite Pharma Corporation Information

Table 121. Kite Pharma Description and Major Businesses

Table 122. Kite Pharma Immune Check Point Inhibitor Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 123. Kite Pharma Product

Table 124. Kite Pharma Recent Development

Table 125. MacroGenics Corporation Information

Table 126. MacroGenics Description and Major Businesses

Table 127. MacroGenics Immune Check Point Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 128. MacroGenics Product

Table 129. MacroGenics Recent Development

Table 130. Merck Corporation Information

Table 131. Merck Description and Major Businesses

Table 132. Merck Immune Check Point Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 133. Merck Product

Table 134. Merck Recent Development

Table 135. NewLink Genetics Corp Corporation Information

Table 136. NewLink Genetics Corp Description and Major Businesses

Table 137. NewLink Genetics Corp Immune Check Point Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 138. NewLink Genetics Corp Product

Table 139. NewLink Genetics Corp Recent Development

Table 140. Sorrento Therapeutics Corporation Information

Table 141. Sorrento Therapeutics Description and Major Businesses

Table 142. Sorrento Therapeutics Immune Check Point Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 143. Sorrento Therapeutics Product

Table 144. Sorrento Therapeutics Recent Development

Table 145. TG Therapeutics Corporation Information

Table 146. TG Therapeutics Description and Major Businesses

Table 147. TG Therapeutics Immune Check Point Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)

Table 148. TG Therapeutics Product

Table 149. TG Therapeutics Recent Development

Table 150. Global Immune Check Point Inhibitor Sales Forecast by Regions (2021-2026) (K Pcs)

Table 151. Global Immune Check Point Inhibitor Sales Market Share Forecast by Regions (2021-2026)

Table 152. Global Immune Check Point Inhibitor Revenue Forecast by Regions (2021-2026) (US$ Million)

Table 153. Global Immune Check Point Inhibitor Revenue Market Share Forecast by Regions (2021-2026)

Table 154. North America: Immune Check Point Inhibitor Sales Forecast by Country (2021-2026) (K Pcs)

Table 155. North America: Immune Check Point Inhibitor Revenue Forecast by Country (2021-2026) (US$ Million)

Table 156. Europe: Immune Check Point Inhibitor Sales Forecast by Country (2021-2026) (K Pcs)

Table 157. Europe: Immune Check Point Inhibitor Revenue Forecast by Country (2021-2026) (US$ Million)

Table 158. Asia Pacific: Immune Check Point Inhibitor Sales Forecast by Region (2021-2026) (K Pcs)

Table 159. Asia Pacific: Immune Check Point Inhibitor Revenue Forecast by Region (2021-2026) (US$ Million)

Table 160. Latin America: Immune Check Point Inhibitor Sales Forecast by Country (2021-2026) (K Pcs)

Table 161. Latin America: Immune Check Point Inhibitor Revenue Forecast by Country (2021-2026) (US$ Million)

Table 162. Middle East and Africa: Immune Check Point Inhibitor Sales Forecast by Country (2021-2026) (K Pcs)

Table 163. Middle East and Africa: Immune Check Point Inhibitor Revenue Forecast by Country (2021-2026) (US$ Million)

Table 164. Key Opportunities and Drivers: Impact Analysis (2021-2026)

Table 165. Key Challenges

Table 166. Market Risks

Table 167. Main Points Interviewed from Key Immune Check Point Inhibitor Players

Table 168. Immune Check Point Inhibitor Customers List

Table 169. Immune Check Point Inhibitor Distributors List

Table 170. Research Programs/Design for This Report

Table 171. Key Data Information from Secondary Sources

Table 172. Key Data Information from Primary Sources

List of Figures

Figure 1. Immune Check Point Inhibitor Product Picture

Figure 2. Global Immune Check Point Inhibitor Sales Market Share by Type in 2020 & 2026

Figure 3. CTLA 4 Product Picture

Figure 4. PD 1 Product Picture

Figure 5. Others Product Picture

Figure 6. Global Immune Check Point Inhibitor Sales Market Share by Application in 2020 & 2026

Figure 7. Medical Care

Figure 8. Experiment

Figure 9. Others

Figure 10. Immune Check Point Inhibitor Report Years Considered

Figure 11. Global Immune Check Point Inhibitor Market Size 2015-2026 (US$ Million)

Figure 12. Global Immune Check Point Inhibitor Sales 2015-2026 (K Pcs)

Figure 13. Global Immune Check Point Inhibitor Market Size Market Share by Region: 2020 Versus 2026

Figure 14. Global Immune Check Point Inhibitor Sales Market Share by Region (2015-2020)

Figure 15. Global Immune Check Point Inhibitor Sales Market Share by Region in 2019

Figure 16. Global Immune Check Point Inhibitor Revenue Market Share by Region (2015-2020)

Figure 17. Global Immune Check Point Inhibitor Revenue Market Share by Region in 2019

Figure 18. Global Immune Check Point Inhibitor Sales Share by Manufacturer in 2019

Figure 19. The Top 10 and 5 Players Market Share by Immune Check Point Inhibitor Revenue in 2019

Figure 20. Immune Check Point Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019

Figure 21. Global Immune Check Point Inhibitor Sales Market Share by Type (2015-2020)

Figure 22. Global Immune Check Point Inhibitor Sales Market Share by Type in 2019

Figure 23. Global Immune Check Point Inhibitor Revenue Market Share by Type (2015-2020)

Figure 24. Global Immune Check Point Inhibitor Revenue Market Share by Type in 2019

Figure 25. Global Immune Check Point Inhibitor Market Share by Price Range (2015-2020)

Figure 26. Global Immune Check Point Inhibitor Sales Market Share by Application (2015-2020)

Figure 27. Global Immune Check Point Inhibitor Sales Market Share by Application in 2019

Figure 28. Global Immune Check Point Inhibitor Revenue Market Share by Application (2015-2020)

Figure 29. Global Immune Check Point Inhibitor Revenue Market Share by Application in 2019

Figure 30. North America Immune Check Point Inhibitor Sales Growth Rate 2015-2020 (K Pcs)

Figure 31. North America Immune Check Point Inhibitor Revenue Growth Rate 2015-2020 (US$ Million)

Figure 32. North America Immune Check Point Inhibitor Sales Market Share by Country in 2019

Figure 33. North America Immune Check Point Inhibitor Revenue Market Share by Country in 2019

Figure 34. U.S. Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 35. U.S. Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 36. Canada Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 37. Canada Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 38. North America Immune Check Point Inhibitor Market Share by Type in 2019

Figure 39. North America Immune Check Point Inhibitor Market Share by Application in 2019

Figure 40. Europe Immune Check Point Inhibitor Sales Growth Rate 2015-2020 (K Pcs)

Figure 41. Europe Immune Check Point Inhibitor Revenue Growth Rate 2015-2020 (US$ Million)

Figure 42. Europe Immune Check Point Inhibitor Sales Market Share by Country in 2019

Figure 43. Europe Immune Check Point Inhibitor Revenue Market Share by Country in 2019

Figure 44. Germany Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 45. Germany Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 46. France Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 47. France Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 48. U.K. Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 49. U.K. Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 50. Italy Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 51. Italy Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 52. Russia Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 53. Russia Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 54. Europe Immune Check Point Inhibitor Market Share by Type in 2019

Figure 55. Europe Immune Check Point Inhibitor Market Share by Application in 2019

Figure 56. Asia Pacific Immune Check Point Inhibitor Sales Growth Rate 2015-2020 (K Pcs)

Figure 57. Asia Pacific Immune Check Point Inhibitor Revenue Growth Rate 2015-2020 (US$ Million)

Figure 58. Asia Pacific Immune Check Point Inhibitor Sales Market Share by Region in 2019

Figure 59. Asia Pacific Immune Check Point Inhibitor Revenue Market Share by Region in 2019

Figure 60. China Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 61. China Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 62. Japan Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 63. Japan Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 64. South Korea Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 65. South Korea Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 66. India Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 67. India Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 68. Australia Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 69. Australia Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 70. Taiwan Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 71. Taiwan Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 72. Indonesia Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 73. Indonesia Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 74. Thailand Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 75. Thailand Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 76. Malaysia Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 77. Malaysia Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 78. Philippines Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 79. Philippines Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 80. Vietnam Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 81. Vietnam Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 82. Asia Pacific Immune Check Point Inhibitor Market Share by Type in 2019

Figure 83. Asia Pacific Immune Check Point Inhibitor Market Share by Application in 2019

Figure 84. Latin America Immune Check Point Inhibitor Sales Growth Rate 2015-2020 (K Pcs)

Figure 85. Latin America Immune Check Point Inhibitor Revenue Growth Rate 2015-2020 (US$ Million)

Figure 86. Latin America Immune Check Point Inhibitor Sales Market Share by Country in 2019

Figure 87. Latin America Immune Check Point Inhibitor Revenue Market Share by Country in 2019

Figure 88. Mexico Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 89. Mexico Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 90. Brazil Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 91. Brazil Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 92. Argentina Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 93. Argentina Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 94. Latin America Immune Check Point Inhibitor Market Share by Type in 2019

Figure 95. Latin America Immune Check Point Inhibitor Market Share by Application in 2019

Figure 96. Middle East and Africa Immune Check Point Inhibitor Sales Growth Rate 2015-2020 (K Pcs)

Figure 97. Middle East and Africa Immune Check Point Inhibitor Revenue Growth Rate 2015-2020 (US$ Million)

Figure 98. Middle East and Africa Immune Check Point Inhibitor Sales Market Share by Country in 2019

Figure 99. Middle East and Africa Immune Check Point Inhibitor Revenue Market Share by Country in 2019

Figure 100. Turkey Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 101. Turkey Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 102. Saudi Arabia Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 103. Saudi Arabia Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 104. U.A.E Immune Check Point Inhibitor Sales Growth Rate (2015-2020) (K Pcs)

Figure 105. U.A.E Immune Check Point Inhibitor Revenue Growth Rate (2015-2020) (US$ Million)

Figure 106. Middle East and Africa Immune Check Point Inhibitor Market Share by Type in 2019

Figure 107. Middle East and Africa Immune Check Point Inhibitor Market Share by Application in 2019

Figure 108. Advaxis Total Revenue (US$ Million): 2019 Compared with 2018

Figure 109. Agenus Total Revenue (US$ Million): 2019 Compared with 2018

Figure 110. Amgen Total Revenue (US$ Million): 2019 Compared with 2018

Figure 111. Bristol Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018

Figure 112. Faron Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018

Figure 113. Genentech Total Revenue (US$ Million): 2019 Compared with 2018

Figure 114. Genocea Total Revenue (US$ Million): 2019 Compared with 2018

Figure 115. Incyte Corporation Total Revenue (US$ Million): 2019 Compared with 2018

Figure 116. Innate Pharma Total Revenue (US$ Million): 2019 Compared with 2018

Figure 117. Kite Pharma Total Revenue (US$ Million): 2019 Compared with 2018

Figure 118. MacroGenics Total Revenue (US$ Million): 2019 Compared with 2018

Figure 119. Merck Total Revenue (US$ Million): 2019 Compared with 2018

Figure 120. NewLink Genetics Corp Total Revenue (US$ Million): 2019 Compared with 2018

Figure 121. Sorrento Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018

Figure 122. TG Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018

Figure 123. North America Immune Check Point Inhibitor Sales Growth Rate Forecast (2021-2026) (K Pcs)

Figure 124. North America Immune Check Point Inhibitor Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 125. Europe Immune Check Point Inhibitor Sales Growth Rate Forecast (2021-2026) (K Pcs)

Figure 126. Europe Immune Check Point Inhibitor Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 127. Asia Pacific Immune Check Point Inhibitor Sales Growth Rate Forecast (2021-2026) (K Pcs)

Figure 128. Asia Pacific Immune Check Point Inhibitor Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 129. Latin America Immune Check Point Inhibitor Sales Growth Rate Forecast (2021-2026) (K Pcs)

Figure 130. Latin America Immune Check Point Inhibitor Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 131. Middle East and Africa Immune Check Point Inhibitor Sales Growth Rate Forecast (2021-2026) (K Pcs)

Figure 132. Middle East and Africa Immune Check Point Inhibitor Revenue Growth Rate Forecast (2021-2026) (US$ Million)

Figure 133. Porter's Five Forces Analysis

Figure 134. Channels of Distribution

Figure 135. Distributors Profiles

Figure 136. Bottom-up and Top-down Approaches for This Report

Figure 137. Data Triangulation

Figure 138. Key Executives Interviewed

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Similar Reports

2020 World Blood Typing, Grouping and Infectious Disease NAT Screening Market in 68 Countries: Supplier Shares and Strategies, Volume and Sales Segment Forecasts for over 40 Tests, Technology and Instrumentation Review

This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.

The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...

  • Publish Date: March 2, 2020
  • $0
Hearing Aids Market in India 2011

Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...

  • Publish Date: March 10, 2011
  • $950
Cardiac Pacemaker Market in India 2011

The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...

  • Publish Date: July 18, 2011
  • $950